Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break
Adial Pharmaceuticals shares were indicated lower ahead of Tuesday’s open, with ADIL at $2.05 in premarket trading — the session before regular market hours — down 1.4% from the previous close of $2.08. U.S. exchanges were shut Monday for Memorial Day and were due to resume normal trading Tuesday. The move is small in dollar terms. It matters because Adial is not trading on sales momentum. It is trading on whether it can fund, partner or delay the next step for AD04, its lead drug candidate for alcohol use disorder.